Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

129.82 +0.97 (+0.75%)
Streaming Delayed Price Updated: 12:16 PM EDT, Apr 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
What Does the Market Think About Abbott Laboratories?
Via Benzinga
Indications Suggest ABBOTT LABORATORIES (NYSE:ABT) Could Be on the Verge of a Breakout.
Exploring ABBOTT LABORATORIES's Technical Signals and Breakout Potential: ABBOTT LABORATORIES is showing promising signs of setting up for a breakout. 
Via Chartmill
3 Reasons ABBV is Risky and 1 Stock to Buy Instead
AbbVie trades at $205.51 per share and has stayed right on track with the overall market, gaining 5.2% over the last six months. At the same time, the S&P 500 has returned 5.1%. 
Via StockStory
Topics Stocks
Exposures US Equities
Medical Devices & Supplies - Diversified Stocks Q4 Teardown: Stryker (NYSE:SYK) Vs The Rest
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at medical devices & supplies - diversified... 
Via StockStory
Q4 Earnings Roundup: Baxter (NYSE:BAX) And The Rest Of The Medical Devices & Supplies - Diversified Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - diversified stocks fared in Q4,... 
Via StockStory
Looking Into Abbott Laboratories's Recent Short Interest
Via Benzinga
This Is What Whales Are Betting On Abbott Laboratories
Via Benzinga
Biotech Stocks Stay Strong Through A Period Of Uncertainty In The Market
Many analysts are feeling better about the prospects for healthcare stocks in 2025. 
Via Talk Markets
Topics ETFs Stocks / Equities
Q4 Earnings Highs And Lows: Neogen (NASDAQ:NEOG) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Neogen (NASDAQ:NEOG) and its peers. 
Via StockStory
Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts highlighted long-term growth potential. 
Via Benzinga
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
Via The Motley Fool
Rep. Emily Randall Has Sold Up to $165K Worth Of Abbott Laboratories Stock: Here's What You Should Know
Via Benzinga
Market Whales and Their Recent Bets on ABT Options
Via Benzinga
Deep Dive Into Abbott Laboratories Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
3 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Via The Motley Fool
Q4 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Boston Scientific (NYSE:BSX)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Boston Scientific (NYSE:BSX) and the best... 
Via StockStory
3 Fabulous Dividend Stocks to Buy in February
Via The Motley Fool
3 Dividend Growth Stocks For Intergenerational Wealth
Long-term investors can create intergenerational wealth with dividend growth investing. 
Via Talk Markets
Topics Stocks / Equities
2 Unstoppable Dividend Stocks That Will Pay You for Life
Via The Motley Fool
AbbVie (NYSE:ABBV) Posts Better-Than-Expected Sales In Q4, Stock Soars
Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 5.6% year on year to $15.1 billion. Its non-GAAP profit of $2.16 per share... 
Via StockStory
Abbott Laboratories (NYSE:ABT) Posts Q4 Sales In Line With Estimates
Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.2% year on year to $10.97 billion. Its non-GAAP profit of $1.34... 
Via StockStory
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Jim Cramer Is Worried About This Consumer Cyclical Stock: 7% Yield? 'Something May Be Wrong Here'
Cramer takes a look at TETRA Technologies, Abbott, Wendy's, Nu Holdings and Casella Waste on the latest edition of "Mad Money." 
Via Benzinga
Abbott To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Abbott Laboratories Will Outperform Healthcare Stocks in 2025
Johnson & Johnson and Abbott Laboratories offer substantial opportunities for investors, but one is a better buy for total returns in 2025 and 2026. 
Via MarketBeat
Why Is Abbott Stock Trading Higher On Thursday?
Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes Care and Medical Devices. 
Via Benzinga
Congressional Trading Report: Rep. Thomas Kean Bought Over $1K In Abbott Laboratories Stock
Via Benzinga
US Stock Futures Trade Mixed After Skirting Record Highs In Last Session: GE Aerospace, American Airlines, Union Pacific In Focus
U.S. stock futures were mixed on Thursday following Wednesday's rally. Futures of benchmark indices were lower except Dow Jones. 
Via Benzinga
Topics Stocks
Exposures US Equities
My Top 5 Stocks to Buy in Early 2025
Via The Motley Fool
S&P 500 Hits New Record As Netflix Reports Strong Results: Investor Sentiment Improves But Greed Index Remains In 'Fear' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.